Turn Therapeutics (TTRX) Other Non Operating Income (2025 - 2026)
Turn Therapeutics' quarterly Other Non Operating Income came in at $5578.0 in Q1 2026, down 89.12% year-on-year from $51285.0 in Q1 2025, and up 30.94% quarter-over-quarter from $4260.0 in Q3 2025.
Turn Therapeutics has reported Other Non Operating Income for 2 years, with the latest figure at $5578.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 89.12% year-over-year to $5578.0; the trailing twelve-month figure through Mar 2026 stood at $61123.0 (changed N/A YoY), and the FY2025 full-year result was $176520.0, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at $5578.0, up from $4260.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $51285.0 in Q1 2025, with the low at $4260.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Turn Therapeutics | 188.06 Mn | 188.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,578.00 |
| Sep 30, 2025 | 4,260.00 |
| Mar 31, 2025 | 51,285.00 |